Lawrence J. Green MD, FAADClinical Professor of Dermatology, George Washington University School of Medicine, Washington, DC; Diplomate, American Board of Dermatology; Member, Board of Directors, American Academy of Dermatology; President, Montgomery County Medical Society, Rockville, Maryland
Lawrence J. Green, MD, is a Clinical Professor of Dermatology at George Washington University School of Medicine in Washington DC. He has a private practice in Rockville, Maryland, where he also oversees, as principal investigator, a large clinical research practice that performs Phase II-IV trials. Dr Green received his medical degree from New York Medical College and completed his residency in dermatology and dermatologic surgery as well as a clinical research fellowship at the University of California, Irvine. He is a diplomat of the American Board of Dermatology.
Dr Green is currently serving an elected term on the American Academy of Dermatology Board of Directors (AAD) and is a past member of the American Society for Dermatologic Surgery’s (ASDS) Board of Directors. He also is a current member of the National Psoriasis Foundation Medical Advisory Board and in the past served 3 terms as a member of the National Psoriasis Foundation Board of the Directors. He received the AAD’s advocate of the year award in 2018, the ASDS President’s Award in 2009 and the ASDS Patient Safety Hero Award in 2015. He has also received Presidential Citations from the AAD in 2011 and 2017. Dr Green serves as an editor for the Journal of Aesthetic and Clinical Dermatoloy and is on the digital editorial board for Cutis and The Dermatologist periodicals. He is an author on over 70 publications.
Dr. Green is an investigator, consultant, or speaker for: Amgen, Abbvie, Almirall, Arcutis, Brickell, Cassiopea, Celgene, Dermavant, Dermira, Janssen, Lilly, MC-2, Novartis, Orthoderm, Revance, SunPharma, Sienna, and UCB.
Recent Contributions to PracticeUpdate:
- IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis
- Efficacy and Safety of Tofacitinib, Peficitinib, Solcitinib, Baricitinib, Abrocitinib, and Deucravacitinib in Plaque Psoriasis
- Safety and Benefit–Risk Profile of Biologics and Oral Treatments for Moderate-to-Severe Plaque Psoriasis
- Assessing Patient-Perceived Side Effects of Biologic Medications for Psoriasis